12.01
Elanco Animal Health Inc stock is traded at $12.01, with a volume of 22.25M.
It is up +26.29% in the last 24 hours and up +34.34% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$9.51
Open:
$10.83
24h Volume:
22.25M
Relative Volume:
4.27
Market Cap:
$4.71B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
30.02
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
+26.69%
1M Performance:
+34.34%
6M Performance:
-17.17%
1Y Performance:
-11.17%
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ELAN
Elanco Animal Health Inc
|
12.01 | 4.71B | 4.45B | 205.00M | 372.00M | 0.40 |
![]()
ZTS
Zoetis Inc
|
155.99 | 69.76B | 9.26B | 2.49B | 2.30B | 5.47 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
15.06 | 48.12B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
HLN
Haleon Plc Adr
|
10.76 | 45.75B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.60 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
306.92 | 13.67B | 2.76B | 1.11B | 898.10M | 22.77 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-09-24 | Initiated | UBS | Buy |
Dec-02-24 | Initiated | Leerink Partners | Market Perform |
Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-05-24 | Upgrade | Stifel | Hold → Buy |
Dec-19-23 | Initiated | Jefferies | Buy |
Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
Jul-21-22 | Downgrade | Goldman | Buy → Sell |
Jul-12-22 | Initiated | Piper Sandler | Neutral |
Nov-18-21 | Initiated | Morgan Stanley | Overweight |
Oct-28-21 | Downgrade | Stifel | Buy → Hold |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
Apr-15-21 | Initiated | Stifel | Buy |
Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Dec-09-20 | Downgrade | Argus | Buy → Hold |
Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-13-20 | Resumed | Credit Suisse | Neutral |
Aug-04-20 | Resumed | Goldman | Buy |
Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jan-10-20 | Initiated | Raymond James | Mkt Perform |
Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-23-19 | Initiated | Barclays | Overweight |
Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
Aug-15-19 | Upgrade | UBS | Sell → Neutral |
May-23-19 | Initiated | Guggenheim | Neutral |
Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
Feb-12-19 | Initiated | William Blair | Mkt Perform |
Jan-23-19 | Initiated | UBS | Sell |
Jan-15-19 | Initiated | Argus | Buy |
Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Elanco (ELAN) Stock Target Raised by Analyst Amid Favorable Quarter | ELAN Stock News - GuruFocus
Elanco Animal Health (ELAN) Sees Strong Q1 Performance and Raises Outlook - GuruFocus
Elanco (ELAN) Stock Trades Up, Here Is Why - Yahoo Finance
Animal Health Elanco Chirps A Solid Quarter Tempered By Soft Q2 EPS Guide - Benzinga
Elanco Animal Health (ELAN) Raises Full-Year Revenue Outlook - GuruFocus
Compared to Estimates, Elanco Animal Health (ELAN) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Elanco Animal Health Inc SEC 10-Q Report - TradingView
Transcript : Elanco Animal Health Incorporated, Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Elanco stock spikes after Q1 beat (ELAN:NYSE) - Seeking Alpha
Elanco Animal Health Beats Q1 Estimates, Faces Revenue Growth ChallengesNews and Statistics - IndexBox
Elanco (ELAN) Beats Earnings Estimates, Raises 2025 Revenue Guidance - GuruFocus
Elanco Animal Health Incorporated (ELAN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Elanco Q1 2025 slides: Revenue guidance raised amid innovation-driven growth - Investing.com Canada
Elanco Animal Health beats Q1 estimates, shares rise over 3% By Investing.com - Investing.com South Africa
Elanco Animal Health beats Q1 estimates, shares rise over 3% - Investing.com Australia
Elanco (ELAN) Revises 2025 Revenue Forecast and Affirms Profit Projections | ELAN Stock News - GuruFocus
Elanco Animal Health Inc (ELAN) Q1 2025 Earnings: EPS of $0.13 Beats Estimate, Revenue at $1,193 Million Surpasses Expectations - GuruFocus
Elanco (NYSE:ELAN) Beats Q1 Sales Targets, Full-Year Outlook Slightly Exceeds Expectations - Yahoo Finance
Elanco (ELAN) Reports Strong Q1 Revenue with Raised 2025 Guidance | ELAN Stock News - GuruFocus
Elanco Animal Health Reports First Quarter 2025 Results | ELAN Stock News - GuruFocus
Elanco Animal Health Reports First Quarter 2025 Results - TradingView
Elanco Animal Health Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by First Trust Advisors LP - Defense World
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL.com
Companion Animal Vaccine Market Is Booming So Rapidly 2025-2032 - openPR.com
Elanco (ELAN) Reports Q1: Everything You Need To Know Ahead Of Earnings - FinancialContent
Elanco Animal Health Sells Xdemvy Royalties To Blackstone in $295 Million Deal - Benzinga
Commit To Buy Elanco Animal Health At $8, Earn 13.1% Using Options - Nasdaq
Elanco Sells Xdemvy Royalty, Milestone Rights to Blackstone Affiliates for $295 Million - marketscreener.com
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human - GuruFocus
Elanco Sells Royalty, Milestone Rights For Lotilaner In Human Health To Blackstone For $295 Mln Cash - Nasdaq
Elanco Sells Royalty And Milestone Rights For Lotilaner In Human Health To Blackstone Accelerates Debt Paydown - marketscreener.com
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown - PR Newswire
Analyzing Ratios: Elanco Animal Health Inc (ELAN)’s Financial Story Unveiled - DWinneX
Renaissance Technologies LLC Has $760,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Cyromazine Market Deep Research Report with Forecast by 2032 | - openPR.com
Elanco Animal Health Inc [ELAN] Shares Fall Approximately -28.51% Over the Year - knoxdaily.com
Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q1 Earnings Expected to Decline - Yahoo Finance
Companion Animal Specialty Drugs Market Is Booming So Rapidly | Elanco, Dechra, Zomedica - openPR.com
Mariner LLC Buys 24,901 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Elanco Board Sued Over Safety, FDA Setbacks for Dog Itch Drug - news.bloombergtax.com
Elanco Animal Health Inc (ELAN) Stock: A Comprehensive 52-Week Review - investchronicle.com
ELAN’s price-to-book ratio: An indicator of the company’s performance - uspostnews.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Elanco Animal Health Inc (ELAN) - Sete News
Poultry Antibiotic Market Set to Witness Significant Growth - openPR.com
Press Release Distribution & PR Platform - ACCESS Newswire
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Envestnet Asset Management Inc. - Defense World
Russell Investments Group Ltd. Decreases Stake in Elanco Animal Health Incorporated (NYSE:ELAN) - Defense World
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Sold by Wells Fargo & Company MN - Defense World
Elanco Animal Health Inc [ELAN] Records 200-Day SMA of $12.48 - knoxdaily.com
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):